• Search History (Register)
  • MeSH Browser
    • Afrikaans
      Albanian
      Arabic
      Armenian
      Basque
      Bengali
      Bulgarian
      Catalan
      Cambodian
      Chinese (Mandarin)
      Chinese (Cantonese)
      Croatian
      Czech
      Danish
      Dutch
      English
      Estonian
      Fiji
      Finnish
      French
      Georgian
      German
      Greek
      Gujarati
      Hebrew
      Hindi
      Hungarian
      Icelandic
      Indonesian
      Irish
      Italian
      Japanese
      Javanese
      Korean
      Latin
      Latvian
      Lithuanian
      Macedonian
      Malay
      Malayalam
      Maltese
      Maori
      Marathi
      Mongolian
      Nepali
      Norwegian
      Persian
      Polish
      Portuguese
      Punjabi
      Quechua
      Romanian
      Russian
      Samoan
      Serbian
      Slovak
      Slovenian
      Spanish
      Swahili
      Swedish
      Tamil
      Tatar
      Telugu
      Thai
      Tibetan
      Tonga
      Turkish
      Ukrainian
      Urdu
      Uzbek
      Vietnamese
      Welsh
      Xhosa
      Apply
    • Adelaide Health Technology Assessment
      Agence d'évaluation des technologies et des modes d'intervention en santé
      Agencia de Evaluacion de Tecnologias Sanitarias
      Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)
      Agencia de Qualitat i Avaluacio Sanitries de Catalunya
      Agency for Care Effectiveness (ACE)
      Agency for Health Technology Assessment and Tariff System
      Agency for Healthcare Research and Quality
      Agenzia Sanitaria e Sociale Regionale (Regional Agency for Health and Social Care)
      All Wales Medicines Strategy Group
      Andalusian Health Technology Assessment Area
      Australian Health Technology Advisory Committee
      Australian Safety and Efficacy Register of New Interventional Procedures-Surgical
      Austrian Institute for Health Technology Assessment
      Basque Office for Health Technology Assessment
      Belgian Health Care Knowledge Centre
      BlueCross BlueShield Association
      British Columbia Office of Health Technology Assessment
      Canadian Agency for Drugs and Technologies in Health
      Canadian Coordinating Office for Health Technology Assessment
      Canadian Task Force on Preventive Health Care
      Canary Health Service
      Cellule Innovation of the AP-HP
      Center for Drug Evaluation
      Center for Medical Technology Assessment
      Center for Outcomes Research and Economic Evaluation for Health
      Centre for Clinical Effectiveness
      Centre for Reviews and Dissemination
      Centre for Technology Assessment at the Swiss Science and Technology Council
      Centre Hospitalier de l'Universite de Montreal
      Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale
      Committee for New Health Technology Assessment
      Conseil d'Evaluation des Technologies de la Santé du Québec
      Coordenação-Geral de Fomento à Pesquisa e Avaliação de Tecnologias em Saúde, Departamento de Ciência e Tecnologia
      Danish Centre for Evaluation and Health Technology Assessment
      Danish Institute for Health Services Research
      ECRI Institute
      European Network for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Finnish Coordinating Center for Health Technology Assessment
      Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore
      German Agency for HTA at the German Institute for Medical Documentation and Information
      Gesundheit Osterreich GmbH
      Hannover Medical School, Medizinische Hochschule Hannover
      Haute Autorité de Santé
      HAYES, Inc.
      Health Council of the Netherlands Gezondheidsraad
      Health Information and Quality Authority (HIQA)
      Health Intervention and Technology Assessment Program
      Health Quality Ontario
      Health Sciences Institute in Aragon (IACS)
      Health Services Assessment Collaboration
      Health Services Utilization and Research Commission
      Health Technology Advisory Committee
      Health Technology and Policy Unit
      Health Technology Assessment Section, Ministry of Health Malaysia
      Health Technology Board for Scotland
      Health Technology Reference Group
      Health Technology Wales
      HTA Region Stockholm
      HTA South
      HTA Unit, University of Calgary
      Institut national d'excellence en sante et en services sociaux
      Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)
      Institute for Clinical and Economic Review
      Institute for Clinical Effectiveness and Health Policy
      Institute for Clinical Evaluative Sciences
      Institute for Clinical Systems Improvement
      Institute for Quality and Efficiency in Health Care (IQWiG)
      Institute of Applied Health Sciences
      Institute of Health Economics
      Institute of Health Economics
      Institute of Health Technology Assessment and Research (IETSI)
      Institute of Technology Assessment
      Israel Center for Technology Assessment in Health Care
      L'Agence Nationale d'Accreditation d'Evaluation en Santé
      Ludwig Boltzmann Institute for Health Technology Assessment
      Malaysian Health Technology Assessment
      Malaysian Health Technology Assessment Unit
      Medical Advisory Secretariat
      Medical Services Advisory Committee
      Monash Business School, Monash University (MBS)
      National Authority for Assessment and Accreditation in Healthcare (INEAS)
      National Committee for Technology Incorporation (CONITEC)
      National Evidence-based healthcare Collaborating Agency
      National Institute for Clinical Excellence
      National Institute for Health and Care Excellence
      New Zealand Health Technology Assessment
      New Zealand National Health Committee
      NIHR Health and Social Care Delivery Program
      NIHR Health Services and Delivery Research programme
      NIHR Health Technology Assessment programme
      NIHR Horizon Scanning Centre
      NIHR Public Health Research programme
      Norwegian Institute of Public Health
      Norwegian Institute of Public Health
      Norwegian Medical Products Agency
      Ontario Health
      Penn Medicine Center for Evidence-based Practice
      Quality Improvement Scotland
      Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)
      Scottish Health Purchasing Information Centre
      Scottish Health Technologies Group
      Scottish Medicines Consortium (SMC)
      State Health Care Accreditation Agency under the Ministry of Health of the Republic of Lithuania
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swedish Agency for Health Technology Assessment and Assessment of Social Services
      Swiss Federal Office of Public Health (FOPH)
      Technology Assessment at SickKids
      Technology Assessment Unit of the McGill University Health Centre (MUHC)
      The Danish Health Technology Council
      The Federal Joint Committee
      The HTA Center of the Stockholm County Council/Gotland
      The Italian National Agency for Regional Health Services (Agenas)
      The National Health Care Institute (ZIN, Zorginstituut Nederland)
      The National Health Care Institute (Zorginstituut Nederland)
      The Netherlands Organisation for Health Research and Development
      The Regional Health Technology Assessment Centre
      TNO
      U. S. Congress. Office of Technology Assessment
      Unidad de Evaluacion de Tecnologias Sanitarias
      Unidad de Tecnologias de Salud
      Unit of Health Economics and Technology Assessment in Health Care
      University HealthSystem Consortium
      University of York
      VA Technology Assessment Program
      Washington Singer Press
      Washington State Department of Labor and Industries (WSDLI)
      Wessex Institute for Health Research and Development
      West Midlands Health Technology Assessment Collaboration
      WorkSafeBC
      Apply
    • Afghanistan
      Albania
      Algeria
      Andorra
      Antigua and Barbuda
      Argentina
      Armenia
      Australia
      Austria
      Azerbaijan
      Bahamas
      Bahrain
      Bangladesh
      Barbados
      Belarus
      Belgium
      Belize
      Benin
      Bhutan
      Bolivia
      Bosnia and Herzegovina
      Botswana
      Brazil
      Brunei
      Bulgaria
      Burkina Faso
      Burundi
      Cambodia
      Cameroon
      Canada
      Cape Verde
      Central African Republic
      Chad
      Chile
      China
      Colombia
      Comoros
      Congo
      Costa Rica
      Cote dIvoire
      Croatia
      Cuba
      Cyprus
      Czech Republic
      Denmark
      Djibouti
      Dominica
      Dominican Republic
      East Timor
      Ecuador
      Egypt
      El Salvador
      Equatorial Guinea
      Eritrea
      Estonia
      Ethiopia
      Fiji
      Finland
      France
      Gabon
      Gambia
      Georgia
      Germany
      Ghana
      Greece
      Grenada
      Guatemala
      Guinea
      Guinea-Bissau
      Guyana
      Haiti
      Honduras
      Hong Kong
      Hungary
      Iceland
      India
      Indonesia
      Iran
      Iraq
      Ireland
      Israel
      Italy
      Jamaica
      Japan
      Jordan
      Kazakhstan
      Kenya
      Kiribati
      North Korea
      South Korea
      Kuwait
      Kyrgyzstan
      Laos
      Latvia
      Lebanon
      Lesotho
      Liberia
      Libya
      Liechtenstein
      Lithuania
      Luxembourg
      Macedonia
      Madagascar
      Malawi
      Malaysia
      Maldives
      Mali
      Malta
      Marshall Islands
      Mauritania
      Mauritius
      Mexico
      Micronesia
      Moldova
      Monaco
      Mongolia
      Montenegro
      Morocco
      Mozambique
      Myanmar
      Namibia
      Nauru
      Nepal
      Netherlands
      New Zealand
      Nicaragua
      Niger
      Nigeria
      Norway
      Oman
      Pakistan
      Palau
      Panama
      Papua New Guinea
      Paraguay
      Peru
      Philippines
      Poland
      Portugal
      Puerto Rico
      Qatar
      Romania
      Russia
      Rwanda
      Saint Kitts and Nevis
      Saint Lucia
      Saint Vincent and the Grenadines
      Samoa
      San Marino
      Sao Tome and Principe
      Saudi Arabia
      Senegal
      Serbia and Montenegro
      Seychelles
      Sierra Leone
      Singapore
      Slovakia
      Slovenia
      Solomon Islands
      Somalia
      South Africa
      Spain
      Sri Lanka
      Sudan
      Suriname
      Swaziland
      Sweden
      Switzerland
      Syria
      Taiwan
      Tajikistan
      Tanzania
      Thailand
      Togo
      Tonga
      Trinidad and Tobago
      Tunisia
      Turkey
      Turkmenistan
      Tuvalu
      Uganda
      Ukraine
      United Arab Emirates
      United Kingdom
      United States
      Uruguay
      Uzbekistan
      Vanuatu
      Vatican City
      Venezuela
      Vietnam
      Yemen
      Zambia
      Zimbabwe
      Apply
Sort by Relevance
CSV RIS
Search Results [121 Hits] Selected Records [0 Hits] [Clear]
Year Source Title
2025 NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental subsegmental pulmonary embolism: the challenges and lessons from the STOPAPE RCT
2024 NIHR Health Technology Assessment programme Evaluation of venous thromboembolism risk assessment models for hospital inpatients: the VTEAM evidence synthesis
2024 NIHR Health Technology Assessment programme Stopping anticoagulation for isolated or incidental pulmonary embolism: the STOPAPE RCT protocol
2024 Health Sciences Institute in Aragon (IACS) [Methods for the quantification of direct-acting oral anticoagulants in plasma]
2024 Austrian Institute for Health Technology Assessment (AIHTA) Point of care tests (POCT): D-dimer and troponin (Update 2024)
2024 NIHR Health Technology Assessment programme Thromboprophylaxis during pregnancy and the puerperium: a systematic review and economic evaluation to estimate the value of future research
2024 Agency for Care Effectiveness (ACE) CavaClear for patients with difficult inferior vena cava filters (IVCFs) retrieval who have failed a previous retrieval method
2023 Health Sciences Institute in Aragon (IACS) [Incorporation of expanded genetic analysis to assist the assessment of venous thromboembolism risks and recurrent spontaneous miscarriages]
2023 Penn Medicine Center for Evidence-based Practice (CEP) Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2022 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Cardiac monitoring with textile wearable Holter for atrial fibrillation detection after cryptogenic stroke]
2022 Penn Medicine Center for Evidence-based Practice (CEP) VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022 Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2021 Canadian Agency for Drugs and Technologies in Health (CADTH) Direct oral anticoagulants for atrial fibrillation [evidence update]
2021 The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of rivaroxaban (Xarelto®) for the treatment of VTE and prevention of VTE recurrence in children
2021 Institute for Clinical Effectiveness and Health Policy (IECS) [Direct-acting oral anticoagulants for postoperative thrombosis prophylaxis]
2020 Malaysian Health Technology Assessment (MaHTAS) Prophylactic anticoagulation in ambulatory cancer patients
2020 Norwegian Institute of Public Health (NIPH) [Intermittent pneumatic compression for preventing deep vein thrombosis in acute stroke, a health technology assessment]
2020 Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with carotid artery disease]
2020 Penn Medicine Center for Evidence-based Practice (CEP) Early mobilization to reduce medical inpatient length of stay and adverse
2020 NIHR Health Technology Assessment programme Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2019 Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Effectiveness and safety of epicardial closure of left atrial appendage using clips by minimally invasive surgery for thromboembolism prevention in patients with atrial fibrillation]
2019 NIHR Health Technology Assessment programme Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation
2019 National Committee for Technology Incorporation (CONITEC) [Diagnostic tests for thrombophilia in pregnancy]
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge, state of practice: Use of direct oral anticoagulants and warfarin in the context of atrial fibrillation and venous thromboembolism]
2019 Institut national d'excellence en sante et en services sociaux (INESSS) [National medical protocols and associated prescriptions: anticoagulant therapy]
2019 Penn Medicine Center for Evidence-based Practice (CEP) Timing of valve replacement for patients with infective endocarditis and intracranial embolism
2019 European Network for Health Technology Assessment (EUnetHTA) Point-of-care tests (POCT): D-dimer and troponin
2018 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2018 Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2017 NIHR Health Technology Assessment programme Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis
2016 NIHR Health Technology Assessment programme Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
2016 Penn Medicine Center for Evidence-based Practice (CEP) Clinical risk prediction scales for venous thromboembolism in hospitalized patients
2016 Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Relevance of adjusting the D-dimer test positivity threshold according to age in patients at low risk of venous thromboembolic events]
2016 NIHR Health Technology Assessment programme Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation
2015 NIHR Health Technology Assessment programme Edoxaban tosylate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [ID662]
2015 NIHR Horizon Scanning Centre (NIHR HSC) Idarucizumab for the reversal of anticoagulation due to treatment with dabigatran – first line
2015 All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Tinzaparin sodium (Innohep®)
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Addendum to Commission A14-28 (apixaban)]
2015 National Institute for Health and Care Excellence (NICE) Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism. NICE technology appraisal guidance 354
2015 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Edoxaban - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 Canadian Agency for Drugs and Technologies in Health (CADTH) Acetylsalicylic acid for venous thromboembolism prophylaxis: an update of clinical evidence
2014 NIHR Horizon Scanning Centre (NIHR HSC) Betrixaban for the prevention of venous thromboembolism – first line
2014 Penn Medicine Center for Evidence-based Practice (CEP) Aspirin for VTE prophylaxis in hip and knee replacement surgery
2014 National Institute for Health and Care Excellence (NICE) The geko device for reducing the risk of venous thromboembolism. NICE medical technologies guidance 19
2014 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2014 NIHR Health Technology Assessment programme Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism [ID726]
2014 National Institute for Health and Care Excellence (NICE) Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 327
2013 NIHR Horizon Scanning Centre (NIHR HSC) Apixaban (Eliquis) for the treatment and prevention of venous thromboembolic events
2013 Penn Medicine Center for Evidence-based Practice (CEP) Thromboelastography-guided heparin use for the prevention of venous thromboembolism
2013 National Institute for Health and Care Excellence (NICE) Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism. NICE technology appraisal guidance 287
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Timing of enoxaparin administration for the prophylaxis of venous thromboembolism: clinical evidence and guidelines
2013 National Institute for Health and Care Excellence (NICE) Percutaneous closure of patent foramen ovale to prevent recurrent cerebral embolic events. NICE interventional procedures guidance 472
2013 The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy and cost-effectiveness of two clinical decision rules for the diagnosis of deep vein thrombosis and pulmonary embolism in residents of nursing homes and homes for the elderly]
2013 Agency for Healthcare Research and Quality (AHRQ) Stroke prevention in atrial fibrillation
2013 Canadian Agency for Drugs and Technologies in Health (CADTH) Risk factors to consider for extended anticoagulant therapy: a review of guidelines
2012 Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2012 Institute for Clinical Effectiveness and Health Policy (IECS) [Prophylaxis for thromboembolic disease with low molecular weight heparins in adult patients in home care]
2012 Institute for Clinical Effectiveness and Health Policy (IECS) [Hyperbaric oxygen therapy in lateral sinus thrombosis]
2012 NIHR Horizon Scanning Centre (NIHR HSC) Edoxaban tosylate for the treatment and secondary prevention of venous thromboembolic events
2012 National Institute for Health and Care Excellence (NICE) Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults. NICE technology appraisal guidance 245
2012 NIHR Health Technology Assessment programme Rivaroxaban for the treatment of deep vein thrombosis and secondary prevention of venous thromboembolism
2012 Canadian Agency for Drugs and Technologies in Health (CADTH) New oral anticoagulants for the prevention of thromboembolic events in patients with atrial fibrillation
2011 NIHR Horizon Scanning Centre (NIHR HSC) Edoxaban tosylate for prevention of stroke and systemic embolic events in non-valvular atrial fibrillation
2011 Institute for Clinical Effectiveness and Health Policy (IECS) [Dabigatran and rivaroxaban as thrombophylaxis after major orthopedic surgery]
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Acetylsalicylic acid for venous thromboembolism prophylaxis: a review of clinical evidence, benefits and harms
2011 Canadian Agency for Drugs and Technologies in Health (CADTH) Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2011 NIHR Horizon Scanning Centre (NIHR HSC) Edoxaban tosylate for prevention of stroke and systemic embolic events in non-valvular atrial fibrillation
2011 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Percutaneuous left atrial appendage closure for the prevention of thrombo-embolic events in patients with atrial fibrillation]
2011 Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke]
2011 National Institute for Health and Care Excellence (NICE) Thoracoscopic exclusion of the left atrial appendage (with or without surgical ablation) for non-valvular atrial fibrillation for the prevention of thromboembolism. NICE interventional procedures guidance 400
2011 NIHR Health Technology Assessment programme Apixaban for the prevention of venous thromboembolism in people undergoing elective knee and hip replacement surgery
2010 NIHR Horizon Scanning Centre (NIHR HSC) Dabigatran etexilate (Pradaxa) for secondary prevention of venous thromboembolism (VTE)
2010 NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for prevention of venous thromboembolism in medically ill patients
2010 NIHR Horizon Scanning Centre (NIHR HSC) Rivaroxaban (Xarelto) for venous thromboembolism
2010 National Institute for Health and Care Excellence (NICE) Percutaneous closure of patent foramen ovale for the secondary prevention of recurrent paradoxical embolism in divers. NICE interventional procedures guidance 371
2010 Adelaide Health Technology Assessment (AHTA) Penumbra system for endovascular thrombus removal for treatment of ischaemic stroke patients
2010 National Institute for Health and Care Excellence (NICE) Percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation for the prevention of thromboembolism. NICE interventional procedures guidance 349
2009 HAYES, Inc. FiberNet Embolic Protection System (EPS) (Lumen Biomedical Inc.)
2009 NIHR Health Technology Assessment programme Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal
2009 Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for bariatric surgery
2009 Canadian Agency for Drugs and Technologies in Health (CADTH) Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis: a review of the cost-effectiveness
2009 Penn Medicine Center for Evidence-based Practice (CEP) Intermittent pneumatic compression devices for venous thromboembolism prophylaxis
2009 Penn Medicine Center for Evidence-based Practice (CEP) Low molecular weight heparins for prevention of venous thromboembolism in total knee arthroplasty patients
2009 Penn Medicine Center for Evidence-based Practice (CEP) Mechanical prophylaxis for venous thromboembolism after ambulatory surgery
2009 Canadian Agency for Drugs and Technologies in Health (CADTH) Dabigatran or Rivaroxaban versus other anticoagulants for thromboprophylaxis after major orthopedic surgery: systematic review of comparative clinical-effectiveness and safety
2009 Blue Cross Blue Shield Association (BCBS) Angioplasty and stenting of the cervical carotid artery with embolic protection of the cerebral circulation
2009 NIHR Health Technology Assessment programme Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal
2009 Institute for Clinical Effectiveness and Health Policy (IECS) Immunoassay D-Dimer test as marker of venous thromboembolism
2009 Agency for Healthcare Research and Quality (AHRQ) Outcomes of genetic testing in adults with a history of venous thromboembolism
2009 HAYES, Inc. Mechanical embolus removal device (Merci Retriever) (Concentric Medical Inc.) for ischemic stroke
2008 The Netherlands Organisation for Health Research and Development (ZonMw) [To test or not to test for thrombophilia after a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs]
2008 Canadian Agency for Drugs and Technologies in Health (CADTH) Fondaparinux versus enoxaparin for the prevention of venous thromboembolism: a comparative clinical and cost-effectiveness review
2008 HAYES, Inc. Factor V Leiden (FVL) for risk assessment for venous thromboembolism (VTE) or obstetric complications
2008 NIHR Horizon Scanning Centre (NIHR HSC) Dabigatran etexilate (Pradaxa) for acute symptomatic venous thromboembolism
2008 HAYES, Inc. Methylenetetrahydrofolate Reductase (MTHFR) C677T for risk assessment for venous thromboembolism (VTE) or obstetric complications
2008 HAYES, Inc. Prothrombin G20210A for risk assessment for venous thromboembolism (VTE) or obstetric complications
2008 NIHR Horizon Scanning Centre (NIHR HSC) AVE-5026 for the prevention of venous thromboembolism in patients at risk
2008 HAYES, Inc. Thrombosis panel for risk assessment for venous thromboembolism (VTE) or obstetric complications
2007 Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for medical inpatients
2007 Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for ischemic stroke